Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $26.1900 (3.64%) ($25.3000 - $26.8100) on Wed. Jun. 20, 2018. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.79% (three month average) | RSI | 24 | Latest Price | $26.1900(3.64%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS declines -1% a day on average for past five trading days. | Weekly Trend | ADMS declines -3.8% a week on average for past two weeks. | Market Behavior | Normal for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) XBI(22%) IBB(20%) XOP(18%) IWO(17%) QQQ(17%) | Factors Impacting ADMS price | ADMS will decline at least -1.395% in a week (0% probabilities). VIXM(-11%) UNG(-10%) BNDX(-10%) UUP(-7%) VXX(-6%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.395% (StdDev 2.79%) | Hourly BBV | 0 () | Intraday Trend | 3.1% | | | |
|
1 - 5 Day Possible Target | $18.9(-27.84%) | Resistance Level | $27.7 | 5 Day Moving Average | $26.17(0.08%) | 10 Day Moving Average | $26.88(-2.57%) | 20 Day Moving Average | $27.7(-5.45%) | To recent high | -19.8% | To recent low | 15.8% | Market Cap | $741m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |